医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Glaukos Corporation Receives Regulatory Approval in Australia for iStent inject®

2015年07月30日 PM10:15
このエントリーをはてなブックマークに追加


 

LAGUNA HILLS, Calif.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) for its iStent inject® Trabecular Micro-Bypass Stent.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150730005242/en/

The Glaukos Corporation iStent inject is preloaded with two stents. Each stent is approximately 0.3  ...

The Glaukos Corporation iStent inject is preloaded with two stents. Each stent is approximately 0.3 mm in diameter and 0.4 mm long. (Photo: Business Wire)

With TGA approval, the iStent inject is now indicated for use in Australia in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate glaucoma currently treated with ocular hypotensive medication.

The iStent inject relies on a similar fluidic method of action as the company’s flagship iStent® Trabecular Micro-Bypass Stent, which was approved by the TGA in 2014. Packaged in a two-stent, preloaded, auto-inject mechanism, the iStent inject allows an ophthalmic surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point for greater IOP reduction. Made from surgical-grade non-ferromagnetic titanium that is coated with heparin, each iStent inject stent is approximately 0.3 mm in diameter and 0.4 mm long, or roughly one-third the size of the original iStent.

“The iStent inject is designed to make it more straightforward for a surgeon to implant two stents in a facile click-and-release motion, providing an important new tool for effectively managing patients’ IOP,” said Thomas Burns, president and CEO of Glaukos. “This approval strengthens our offering to Australian surgeons and patients, and underscores our commitment to expand our presence in the Asia Pacific region.”

According to Glaucoma Australia, a not-for-profit glaucoma awareness, education and support association, more than 300,000 people in Australia suffer from glaucoma, which is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for the disease and reducing IOP is the only proven treatment.

The iStent inject is already approved in the European Union and an initial commercial launch is underway in Germany. Glaukos is also pursuing regulatory approval in other countries, including the United States where the company is conducting IDE clinical trials to evaluate two versions of the iStent inject, one in combination with cataract surgery and another as a standalone procedure in phakic and pseudophakic glaucoma patients.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies and prospects regarding, among other things, our iStent and iStent inject® products, efforts to secure regulatory approvals, and U.S. and international commercialization efforts. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. The known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC) and available in the Investor section of our website at www.glaukos.com or at www.sec.gov.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150730005242/en/

CONTACT

for Glaukos Corporation
Media Contact:
Cassandra Dump
(619)
971-1887
cassy@pascalecommunications.com
or
Investor
Contact:

Sheree Aronson
VP, Investor Relations
(949)
367-9600 ext 371
saronson@glaukos.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent